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hemophilia treatments
Comment on:  the  mutation  F309S  increases  FVIII
secretion in human  cell lineBidossessi Wilfried Hounkpe, Erich Vinicius de Paula ∗
Universidade Estadual de Campinas (Unicamp), Campinas, SP, BrazilThe implementation of prophylaxis with regular factor VIII
(FVIII) replacement for patients with hemophilia radically
changed the clinical presentation of this condition, from a dis-
ease characterized by progressive disabling musculoskeletal
complications, to one compatible with an active and virtually
normal lifestyle. In Brazil, although most adults with severe
hemophilia still suffer the impact of musculoskeletal com-
plications in their quality of life,1 the recent implementation
of universal prophylaxis will certainly change this situation
for the next generation of patients. This scenario posits a
challenge to government and healthcare providers, for whom
guaranteeing a reliable and safe source of FVIII concentrate
has become more  than ever, a strategic issue. This is the con-
text that underscores the importance of the study by Fantacini
et al. in this issue of the Revista Brasileira de Hematologia e
Hemoterapia, in which the authors used a combined strategy
to improve recombinant FVIII production, based on ‘rational
mutagenesis’, chemical chaperones, and human cell lines.2
Rational mutagenesis consists in the introduction of DNA
variations (and hence, amino acid changes) aimed at improv-
ing the function of a recombinant protein, based on previous
knowledge about protein structure and function. The power of
rational mutagenesis was well-illustrated by the identiﬁcation
in 1988 of a residue in coagulation factor IX (FIX) whose change
DOI of original article: http://dx.doi.org/10.1016/j.bjhh.2016.04.002.
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report of an analogous change in this very residue in a family
with extremely high levels of FIX activity.4 In this report, the
authors used a FVIII variant with a point mutation (FVIII F309S)
in a region that determines the magnitude of ATP-dependence
of FVIII secretion. This mutation was rationally designed in
1997 by Swaroop et al., based on a previous demonstration
that this speciﬁc region of FVIII could bind a protein that
limited its secretion.5 By changing a single amino acid in this
region, based on the structure of factor V, the authors were
able to decrease the ATP-dependence of the secretion process,
thereby enhancing production by 2.3-fold, with no apparent
impact on protein function. Fantacini et al. went further, by
introducing this mutation in a human cell line (HEK), and
coupling this strategy with the use of chemical chaperones
to further improve FVIII secretion. Although the use of
chaperones only improved wild type FVIII secretion (possibly
because little or no FVIII F309S was left to be secreted), the
authors were able to reproduce the results of Swaroop et al. in
a human cell line, and to demonstrate that recombinant FVIIIro de Hematologia e Hemoterapia, Rua Carlos Chagas, 480, 13104-
F309S maintained normal function as measured both in vitro
and in vivo, in a tail clip assay in hemophilia A mice.2
One of the major issues of site-speciﬁc mutagenesis
in protein engineering is its still widely unpredictable
 e Terapia Celular. Published by Elsevier Editora Ltda. This is an
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mmunological consequences. In fact, the extreme sensitivity
f the immune system to even minor changes was demon-
trated by the development of inhibitory antibodies in patients
xposed to a factor VIIa variant (vatreptacog alpha), character-
zed by a 3-amino acid change that increased its activity, but
urned it into a immunogenic molecule.6 The fact that this
utcome was not anticipated in animal models highlights the
mportance of very careful pre-clinical and clinical develop-
ent programs for bioengineered proteins.
Another important aspect of the report of Fantacini et al.
s that, as opposed to the vast majority of currently available
ecombinant FVIII products (expressed in rodent cell lines),
he authors use a human cell line in their expression system.
esides limiting the exposure to animal proteins, the use of
uman cell lines can reduce differences in post-translational
odiﬁcations in the expressed protein. This could be par-
icularly interesting in this ﬁeld, since the development of
nhibitory antibodies to FVIII is currently the main challenge
f hemophilia treatment. Although the clinical relevance of
his strategy to inhibitor development is yet to be proved, the
ecent introduction of the ﬁrst commercial recombinant FVIII
roduct expressed in a human cell line7 will allow this hypoth-
sis to be tested.
In conclusion, the study of Fantacini et al. represents an
dditional step of a Brazilian group toward mastering the
echnology of recombinant coagulation factor concentrate
roduction,8 which as previously stated, should be regarded
s a strategic area of research.onﬂict  of  interest
he authors declare no conﬂicts of interest. 1 6;3  8(3):184–185 185
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